Become Affiliate

PepFlow

Download

The Immune Modulator

Thymosin Alpha-1

Thymosin alpha-1 is a 28-amino-acid thymic peptide, also called thymalfasin, studied and used internationally as an immune modulator.

Immune modulationImmune recovery
TierB
EvidenceModerate
SafetyModerate Data
FDA statusNot Approved
Last reviewed August 11, 2026 32 citations How to read these labels

What is Thymosin Alpha-1?

Thymosin alpha-1 is a 28-amino-acid thymic peptide, also called thymalfasin, studied and used internationally as an immune modulator.[1][2][3]

Its best-known clinical settings include chronic viral hepatitis, immune dysfunction, vaccine-response adjunct research, and infection-related immune modulation.[1][2][3]

U.S. status is separate from international use: thymalfasin products may exist abroad, but thymosin alpha-1 is not FDA-approved as a U.S. drug product.[1][2][3]

What Thymosin Alpha-1 is investigated for

Thymosin Alpha-1 evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Immune system modulation

Injectable

68%Moderate

Immune modulation is the broadest thymosin alpha-1 claim, while condition-specific claims need separate evidence grades.[1][6][3]

Human evidence

Reviews describe thymosin alpha-1 as an immune-system modulator with clinical use in several infectious-disease contexts outside the U.S. approval framework.[1][6][3]

Animal / mechanistic evidence

Mechanistic literature supports T-cell and innate/adaptive immune modulation.[1][6][3]

Hepatitis B and C adjunct treatment

Injectable

66%Moderate

Viral hepatitis is specifically human-studied and is not the same as generic immune support.[5][7][8]

Human evidence

Chronic hepatitis B literature and meta-analysis support thymosin alpha-1 as an adjunct or historical therapy in viral hepatitis contexts.[5][7][8]

Animal / mechanistic evidence

The hepatitis rationale follows immune enhancement rather than direct antiviral substitution.[5][7][8]

Vaccine response and antiviral adjunct support

Injectable

58%Emerging

Vaccine and antiviral-adjunct support has limited human evidence, not general infection-prevention evidence.[6][2][3]

Human evidence

Reviews describe vaccine-response and antiviral-adjunct applications, but the evidence is less uniform than the hepatitis literature.[6][2][3]

Animal / mechanistic evidence

Immune-modulation mechanisms provide plausibility for vaccine and antiviral-adjunct research.[6][2][3]

Acute illness and post-viral immune support

Injectable

44%Preliminary

Acute and post-viral immune support remains preliminary and condition-specific.[3][2][6]

Human evidence

Broader viral-infection reviews discuss thymosin alpha-1 in acute and post-viral immune contexts, but U.S. approval-level evidence is not established.[3][2][6]

Animal / mechanistic evidence

Mechanistic immune effects support the rationale, while condition-specific outcomes vary.[3][2][6]

Evidence snapshot

68%

Human evidence

Moderate

Clinical literature and reviews exist for immune and infection-related settings, especially outside the U.S. The evidence is meaningful but indication-specific.[1][2][3]

34%

Animal / preclinical

Limited

Mechanistic work supports T-cell, dendritic-cell, and innate immune modulation.[1][2][3]

68%

Mechanism support

Moderate

Thymosin alpha-1 is discussed around T-cell, dendritic-cell, interferon, and innate immune signaling. The mechanism fits immune-response coordination rather than direct antimicrobial action.[1][2][3]

Forms & administration

Thymosin Alpha-1 is tracked as an injectable immune-modulating peptide. Thymalfasin-style clinical use is separate from compounded or research-market products.[17][18][1]

Injectable

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common injectable protocols use 1.5 mg per dose.[17][18][1]

Timing Considerations

Morning is the usual timing.[17][18][1]

What to expect

First weeks

Injectable Thymosin Alpha-1 immune-oriented use may show up as changes in fatigue, infection burden, inflammatory symptoms, or immune-lab patterns.[1][2][3][17][18]

Weeks 6-12

Injectable immune-response blocks may show changes in symptom frequency, viral or inflammatory context, and concurrent-therapy response.[1][2][3][17][18]

After stopping

Immune-marker or symptom patterns may drift after injectable Thymosin Alpha-1 ends if the underlying condition remains active.[1][2][3][17][18]

Safety profile

Thymosin Alpha-1 safety is injectable and immune-focused: injection reactions, fatigue, headache, immune disease context, concurrent therapy, and compounding quality matter.[17][1][2][3]

Common side effects

Cautions

What we don't know

Optimal duration, repeated-cycle safety, interaction effects with immunotherapies, and U.S. compounded-product consistency remain uncertain.[17][1][2][3]

Who Thymosin Alpha-1 is not for

Route-specific avoid and medical-review notes:

  • Pregnancy or breastfeeding unless supervised

    Pregnancy or breastfeeding unless supervised warrants medical review or avoidance for Thymosin Alpha-1.[17][1][2][3]

  • Transplant immunosuppression without specialist review

    Transplant immunosuppression without specialist review warrants medical review or avoidance for Thymosin Alpha-1.[17][1][2][3]

  • Autoimmune flare without clinician oversight

    Autoimmune flare without clinician oversight warrants medical review or avoidance for Thymosin Alpha-1.[17][1][2][3]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Immunosuppressants / transplant drugs

    Tacrolimus, cyclosporine, mycophenolate, steroids, or transplant regimens can conflict with immune-stimulation goals; this is an immune-modulation caution.[17][1][2][3]

  • Checkpoint inhibitors / biologics

    Checkpoint inhibitors, cytokines, or immune biologics can make inflammatory or autoimmune symptoms harder to attribute; this is an immune-modulation caution.[17][1][2][3]

  • Vaccines / immune supplements

    Vaccines or strong immune-stimulant supplements can overlap with fever, fatigue, and immune-response tracking; this is an immune caution.[17][1][2][3]

How it works

Thymosin alpha-1 is discussed around T-cell maturation, dendritic-cell signaling, interferon pathways, innate immune coordination, and antiviral host response. In plain terms, it is an immune-response modulator rather than a direct antimicrobial drug.[1][2][3]

Injectable thymalfasin-style exposure makes the clinical context important. The same immune-modulating position can be useful or risky depending on infection status, cancer status, immune suppression, autoimmune history, and whether it is used as adjunctive therapy. Protocol meaning depends on a defined immune problem and route, not broad immune support.[1][2][3]

Research gaps & open questions

What the current literature has not yet settled about Thymosin Alpha-1:

01

Modern trials need to show whether Thymosin Alpha-1 adds benefit to today's antiviral or cancer treatments, not older treatment standards.[1][2][3]

02

Studies and independent testing need to show whether U.S. compounded products match studied formulations in identity, strength, purity, and clinical effect.[1][2][3]

03

Long-term safety is not established for repeated off-label 'immune wellness' use in otherwise healthy people.[1][2][3]

Common questions

Is thymosin alpha-1 FDA-approved in the United States?

No. Thymosin alpha-1 is not FDA-approved as a U.S. drug product, and FDA lists it with compounding safety concerns.[18][19][17][1][24][22]

Is thymosin alpha-1 approved internationally?

Yes, in some country-specific thymalfasin approvals. EU/Europe, UK, Canada, and Australia status still needs product-by-product regulatory checking.[18][19][17][1]

Is it just an immune booster?

No. It is better described as an immune-modulating mechanism; boosting is too vague and can be unsafe in autoimmune or transplant contexts.[18][19][17][1]

Myths & misconceptions

Myth

Everyone benefits from immune boosting.

Reality

Immune modulation can be harmful in autoimmune, transplant, cancer, or infection contexts.[1][2][3]

Myth

International use means U.S. approval.

Reality

Regulatory status is country-specific.[1][2][3]

History & discovery

Thymosin alpha-1 emerged when thymic-fraction research separated a defined 28-amino-acid immune peptide from crude thymus extracts. Its history is immunology first, not general wellness. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[1][2][3]

Isolation and characterization of thymosin alpha-1 turned a broad thymus-extract story into a specific immune-modulating molecule. That made clinical development and product identity more interpretable.[1][2][3]

Historical reviews describe thymalfasin use in infectious-disease contexts outside the United States. That shaped international familiarity while leaving U.S. approval and compounded-product questions separate.[1][2][3]

Published research32 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Bring consistency to your well-being routine.

Use PepFlow to record your Thymosin Alpha-1 protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00